Bevacizumab is mainly used for the first-line treatment of metastatic colorectal cancer, as well as some advanced non-small cell lung cancers. Specific usage and dosage: It can be administered by intravenous drip at 5 mg/kg every fourteen days. After the application of sodium chloride dilution, the first drip should be given after chemotherapy for more than 90 minutes, and subsequent doses can also be given before or after chemotherapy. The duration of the drip can be shortened if it is well tolerated. Therefore, when applying bevacizumab, it is important to take the appropriate selection method for the patient’s symptoms. In addition some adverse reactions, such as bleeding, arterial thrombosis, diarrhea, nausea, pain and other symptoms, can be reduced appropriately or given the appropriate symptomatic treatment. For congestive heart failure, leukopenia and more serious bleeding from mucous membranes and skin, the drug should be stopped immediately and other options should be selected for treatment.